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Summary
AIMS OF THE STUDY: Adverse drug reactions (ADRs)
are an important cause of hospital admissions. Insufficient
data are available about the frequency and characteristics
of ADR-related emergency readmissions in Switzerland.
The aim of this retrospective study was to characterise
ADRs related to short-term emergency readmissions in a
large Swiss University Hospital and to assess their report-
ing frequency.
METHODS: Electronic records of all patients discharged
from the University Hospital Bern within a 12-month period
(1 January to 31 December 2012) and emergency read-
mission within 30 calendar days were reviewed. Case in-
clusion required a known ADR. Cases with intentional
overdosing, lack of compliance or insufficient documen-
tation were excluded. Identified ADR-related readmission
cases were searched in the Swiss ADR reporting system
to assess reporting rate.
RESULTS: There were 1294 emergency readmissions
among the 4792 readmissions (14% of all admissions)
within 30 days after discharge. We identified 270 cases
of ADR-related readmissions, corresponding to 21% of
emergency readmissions and 6% of all readmissions with-
in 30 days. The most frequent ADRs were gastrointestinal
disorders (26%), infections and infestations (19%), and
nervous system disorders (10%). The most frequent drug
classes leading to ADRs were antineoplastic/immunomod-
ulating (35%) and antithrombotic agents (25%). Only 8
(3%) of the 270 cases were reported to the Swiss ADR re-
porting system.
CONCLUSION: ADR-related readmissions constituted a
considerable part of short-term emergency readmissions.
Despite being a relevant cause for rehospitalisation, only
a minority of the ADRs were reported to the regulatory au-
thorities. Strategies to prevent ADR-related readmissions
and to improve reporting rates are needed.
Keywords: adverse drug reactions, hospital readmission,
emergency readmission, pharmacovigilance, drug safety
Introduction
Adverse drug reactions (ADRs) are unintended noxious re-
sponses to medicinal products and can present a major bur-
den on health care [1, 2]. Approximately 3-5% of hospi-
tal admissions are estimated to be related to ADRs [2–4],
with even higher rates in geriatric populations [5]. Patients
hospitalised owing to an ADR have a significantly pro-
longed length of hospital stay and an almost 2-fold in-
creased risk of death compared with other hospitalised pa-
tients [6]. Therefore, efforts to decrease ADRs are essential
to reduce patient harm and healthcare costs.
Hospital readmissions are increasingly used as a measure
of healthcare quality [7]. According to a recent systematic
review including 19 studies, the median prevalence rate of
drug-related hospital readmissions was 21%, with an es-
timated preventability of 69% [7]. Hospital readmissions
shortly after hospital discharge represent a subgroup of
great interest in terms of preventive measures and quality
improvement. Although short-term hospital readmissions
can be associated with non-drug related causes such as pre-
mature discharge due to pressure on beds, poor commu-
nity support services and medical complications [8], in a
previous study from the United States nearly one-fourth
of the cases with hospital readmission within 30 days had
a contributing ADR [9]. In a German study, ADRs led to
hospitalisation in 6.2% of first admissions and in 4.2% of
readmissions [10]. In some cases, a combination of the
above-mentioned reasons may lead to a short-term read-
mission; for example, an ADR caused by a new drug ther-
apy started during hospitalisation might not be detected in
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costs, with short-term readmission as a possible conse-
quence [10]. Importantly, approximately half of the ADRs
leading to hospital admission have been found to be pre-
ventable [8, 10], which highlights the importance of ADR
monitoring in clinical practice to optimise patient care and
public health.
Spontaneous ADR reports transmitted from health profes-
sionals to drug regulatory authorities play an important
role in providing postmarketing pharmacovigilance data.
In Switzerland, ADR reports are processed by regional
pharmacovigilance centres and Swissmedic’s national
pharmacovigilance centre, which collaborates with the in-
ternational centre for drug safety run by the World Health
Organization (WHO) [11]. In accordance with the new
Law on Therapeutic Products [12], all serious adverse re-
actions must be reported. ADRs are considered serious if
they result in death, are life-threatening, lead to or pro-
long hospitalisation, involve a persistent disability or inca-
pacity, or are otherwise to be considered medically signifi-
cant (e.g., when a timely medical intervention was needed
to prevent one of the above-mentioned outcomes). Sponta-
neous reports can contribute to drug safety by generating
signals of possible ADRs that can then be followed more
closely.
Investigation of ADR-related readmissions can contribute
to the identification of vulnerable groups and high-risk
drugs and to public health by offering guidance regarding
preventive measures. Currently, insufficient data are avail-
able regarding the frequency and characteristics of ADR-
related emergency readmissions in Switzerland. The main
aim of this retrospective study was to characterise ADRs
leading to short-term emergency readmissions in a large
Swiss University Hospital. Further, we aimed to assess the
reporting frequency of such ADRs to the Swiss national
pharmacovigilance centre.
Materials and methods
This retrospective study included all ADR-related read-
missions presenting to the emergency department of the
University Hospital Bern within 30 days after hospital dis-
charge between 1 January and 31 December 2012. The
emergency department of the University Hospital Bern is
both a primary care facility (walk-in patients) and tertiary
referral centre for hospitals in the greater Bern area (pa-
tients ≥16 years of age), with about 48,000 emergency
admissions a year (2018). The division of Clinical Phar-
macology and Toxicology of the hospital also hosts the lo-
cal regional pharmacovigilance centre, which receives and
processes ADR reports and forwards them to the nation-
al pharmacovigilance centre (Swissmedic). The study was
reviewed by the local ethics committee (Cantonal Ethics
Committee Bern).
Cases were identified by reviewing the electronic records
of all patients discharged from the University Hospital
Bern within the 12-month period with emergency readmis-
sion within 30 calendar days after hospital discharge. The
follow-up period of 30 days has been commonly used in
previous studies investigating drug-related hospital read-
missions [7], and hospital readmission within 30 days of
discharge has also been described as a standard measure-
ment of hospitalisation quality [13]. Case inclusion re-
quired a known ADR (listed in the official Swiss [14] or
US drug information [15]) and, in line with the definition
of ADRs [1], a temporal relationship between the ADR and
drug intake. Cases were included if the reason for the read-
mission was an ADR (causality could be possible, prob-
able or certain). The assessment was based on the reason
of admission as stated in the emergency department report
and information on patient history (medication history).
In some, but not all, cases the drug cause was mentioned
in the admission diagnosis section. Cases with intentional
overdosing, evident lack of compliance, insufficient doc-
umentation, decreasing symptoms despite continuation of
the suspected drug(s), or readmitted for non ADR-related
signs and symptoms (e.g., in the context of the patient’s
primary disease, cases of violent assaults) were excluded.
Patient records were reviewed independently by two expe-
rienced medical professionals and unclear cases (divergent
opinions of the two primary assessors) were additionally
reviewed together with a senior physician with experience
in this field. Identified cases were searched in the Swiss
ADR reporting system to assess the reporting rate. A flow-
chart of the procedures is shown in figure 1.
An ADR was defined as “an appreciably harmful or un-
pleasant reaction, resulting from an intervention related to
the use of a medicinal product, which predicts hazard from
future administration and warrants prevention or specif-
ic treatment, or alteration of the dosage regimen, or with-
drawal of the product” [1]. Drugs were classified using
the WHO classification system based on the Anatomical
Therapeutic Chemical (ATC) code, a unique code assigned
to a medicine according to the organ or system it acts on
and how it works [16]. For the evaluation of drug inter-
actions, the drug interaction screening programme Phar-
mavista was used [17]. For the description of ADRs, the
WHO Adverse Reaction Terminology (WHO-ART) Low-
est Level Terms (LLTs) were used to provide maximum
specificity [18]. The causality assessment was based on the
Swiss ADR reporting system criteria (table 1) [19], which
are based on the WHO Uppsala Monitoring Centre (UMC)
causality assessment system [20].
For the investigation of differences between the ADR-re-
lated readmissions (study population) and non ADR-relat-
ed emergency readmissions during the study period, for
which data were collected on age, sex, days between first
hospitalisation and readmission, and duration of hospital-
isation after readmission, comparisons were tested using
the chi-square test for categorical variables, the t-test for
normally distributed continuous variables, and the Mann-
Whitney test for nonparametric variables. Values of p
<0.05 were considered statistically significant. Statistical
analyses were conducted using SPSS statistical software
(IBM SPSS Statistics 25.0).
Results
During the study period there were 4792 readmissions
(14% of all admissions) within 30 days after discharge
and 1294 (27% of all readmissions) of these were emer-
gency readmissions. We identified 270 cases of ADR-re-
lated emergency readmissions, corresponding to 21% of
emergency readmissions and 6% of all readmissions within
30 days. Nine hundred and sixty-one cases were not ADR-
related and in 63 cases an adequate evaluation was not pos-
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sible because of insufficient or missing documentation (fig.
2).
Among the 270 cases of ADR-related readmissions, 78%
were readmitted from home and 22% from a medical in-
stitution (hospital or rehabilitation facility). Most patients
were elderly (59% ≥65 years old) and were male (63%).
The median number of drugs on readmission was 8 (range
0–22; causative drugs already discontinued before presen-
tation at the emergency department in 2 cases and no infor-
mation on the number of drugs available in 32 cases). The
median number of (active) main diagnoses was 6 (range
1–18). In 125 cases (46%), the ADR was associated with
a drug that was newly started or changed during the index
hospitalisation, in 136 cases (50%) the associated drug was
either unchanged or started after the index hospitalisation,
and in 9 cases (3%) an evaluation was not possible be-
cause of insufficient information. ADR-related cases were
Figure 1: Flowchart of the procedures used for the identification of adverse drug reaction (ADR)-related emergency readmissions. (* = Listed
in the official Swiss or US drug information.)
Table 1: Causality assessment criteria [19].
Causality term Assessment criteria
Certain – Temporal relationship to drug intake
– Response to withdrawal (dechallenge)
– Recurrence after reexposure to drug (rechallenge)
– Other proof of causality, e.g. response to specific antidote
Probable/likely – Temporal relationship to drug intake
– Response to withdrawal (dechallenge)
– Unlikely to be attributed to other (non-drug) cause
Possible – Time relationship to drug intake
– Could also be explained by other (non-drug) cause
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significantly older than the non-ADR-related cases, while
no significant differences were found regarding sex, num-
ber of days between discharge of first hospitalisation and
rehospitalisation as well as duration of rehospitalisation
(table 2). The most frequent ADRs leading to hospital
readmission were gastrointestinal disorders (69 cases,
26%), infections and infestations (52 cases, 19%), and
nervous system disorders (27 cases, 10%) (table 3). A
total of 477 drugs were classified as possible causes of
ADR-related hospital readmissions (more than one drug
involved in some cases). The most frequent drug classes
were antineoplastic/immunomodulating (35%), antithrom-
botic agents (25%), and nervous system drugs (16%); the
most frequent chemical subgroups were glucocorticoids
(11%), platelet aggregation inhibitors (9%), heparins (8%),
vitamin K antagonists (7%), calcineurin inhibitors (5%)
and other immunosuppressants such as mycophenolate or
mTOR (mammalian target of rapamycin) inhibitors (4%)
(supplementary table S1 in appendix).
In 231 cases (86%), the ADR concerned a reaction to the
drug itself, in four cases (2%) an ADR was caused by a
drug-drug interaction (DDI), and in 35 cases (13%) both.
The four cases in which a DDI led to an ADR included hy-
ponatraemia under the combination of oxcarbazepine, hy-
drochlorothiazide and citalopram, hyperammonaemic en-
cephalopathy under the combination of valproic acid and
topiramate, drug-induced delirium under ritonavir and mi-
dazolam, and a fatal case of acute renal failure under
perindopril, indapamide, torasemide and lercanidipine.
Further details about cases with fatal outcome can be found
in table 4.
The further 31 cases with ADRs caused not only by the
drugs themselves but also by a DDI included cases with
increased risk of bleeding (drugs involved: acetylsalicylic
acid, clopidogrel, nadroparin, enoxaparin, heparin, phen-
procoumon, acenocoumarol, escitalopram, ibuprofen,
ciprofloxacin, dexamethasone), one case of increased tox-
icity of fluoropyrimidines (drugs involved: fluorouracil,
calcium folinate), one case of increased risk of extended
respiratory depression and sedation (drugs involved: mor-
phine, flunitrazepam), one case of a skin reaction in a pa-
tient treated with lamotrigine and valproic acid, and one
case with two interactions, blood pressure decrease (can-
desartan, hydrochlorothiazide) and hyponatraemia and
ventricular arrhythmias (hydrochlorothiazide, trim-
ipramine).
With respect to causality, according to the Swiss ADR re-
porting system causality criteria, most cases (244, 90%)
were assessed as “possible”, 24 (9%) as “probable/likely”
(table S2), and two (<1%) as “certain” (one case of he-
parin-induced thrombocytopenia under nadroparin and one
case of accidental drug overdose under tacrolimus).
In accordance with the new Law on Therapeutic Products
[12], all ADRs of the study were classified as “serious” as
they led to (re-)hospitalisation; in 228 of the cases (84%),
this was the only criterion for “seriousness”, 34 cases
(13%) required admission to the intensive care unit and
were thus considered to be life-threatening (table S3), and
8 cases (3%) were fatal (table 4). Despite fulfilled criteria
for seriousness in all of the included cases, only 8 (3%) of
the 270 cases and none of the fatal cases were reported to
the Swiss ADR reporting system (table 5).
Discussion
Our data show that ADR-related readmissions constitute
a considerable part of short-term emergency readmissions.
Figure 2: Number of cases of non-emergency readmissions and adverse drug reaction (ADR)- and non-ADR-related emergency readmis-
sions.








Age (years), median (range) 64 (17–95) 67 (17–91) 63 (17–95) <0.001
Female, n (%) 467 (38) 99 (37) 368 (38) 0.626
Days between first hospitalisation and readmission, median
(range)
9 (0–30) 8 (0–30) 9 (0–30) 0.172
Duration of hospitalisation after readmission in days, median
(range)
6 (0–100) 7 (1–82) 6 (0–100) 0.089
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Table 3: Adverse drug reaction (ADR)-related readmission cases by system organ class (n = 270).
MedDRA system organ class Number of cases Details (n)
Gastrointestinal disorders 69 Gastrointestinal bleeding (25)
Obstipation (17)














Infections and infestations 52 Pneumonia (9)
Urosepsis (5)









C. difficile infection recurrence (1)
Erysipelas (1)
Escherichia coli bacteraemia (1)


























Injury, poisoning and procedural complications 20 Bleeding postoperative (11)
Haematoma (5)
Fall (2)
Drug overdose accidental (1)
Wound dehiscence (1)
Renal and urinary disorders 15 Macroscopic haematuria (5)
Acute prerenal failure (3)





General disorders and administration site conditions 12 Fever (6)
Asthenia (2)
Chills and fever (1)
Fatigue (1)
Wound healing delayed (1)
Wound healing disturbance of (1)
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MedDRA system organ class Number of cases Details (n)
Vascular disorders 8 Haematoma (3) Hypertension exacerbated (2) Bleeding varicose vein (1)
Breast bleeding (1) Leucocytoclastic vasculitis (1)
Skin and subcutaneous tissue disorders 7 Exanthema (6) Toxic epitheliolysis (1)
Metabolism and nutrition disorders 6 Hyponatraemia (3) Arthritis gouty (1) Hypotonic dehydration (1) Lactic acido-
sis syndrome (1)
Musculoskeletal and connective tissue disorders 5 Gonarthritis (1) Jaw fracture (1) Joint bleeding (1) Low back pain (1) Muscle
bleeding (1)
Endocrine disorders 4 Hypoglycaemia (2) Adrenocortical insufficiency acute (1) Secondary adrenal
insufficiency (1)
Hepatobiliary disorders 4 Acute cholecystitis (1) Cholangitis (1) Decompensated cirrhosis (1) Drug-in-
duced liver injury (1)
Psychiatric disorders 3 Delirium (2) Drug psychoses, other (1)
Immune system disorders 2 Anaphylactic reaction to drug (2)
Investigations 1 Electrocardiogram QT prolonged (1)
CMV = cytomegalovirus; MedDRA = Medical Dictionary for Regulatory Activities; MRSA = methicillin-resistant Staphylococcus aureus
The most frequent ADRs associated with emergency read-
missions within 30 days after hospital discharge were gas-
trointestinal disorders (approximately one-fourth of the
cases, including cases of gastrointestinal bleeding), as well
as infections and infestation, (approximately one-fifth of
the cases). In line with this, the most frequent drug classes
involved were antineoplastic/immunomodulating and an-
tithrombotic agents, and most (five out of eight) fatal cases
were bleeding related. Despite fulfilling the criteria for se-
riousness, only a minority of the ADRs leading to emer-
gency readmissions was reported to the regulatory authori-
ties.
Table 4: Adverse drug reaction (ADR)-related fatal cases (death in possible relation to ADR and not cases of patients who died during hospitalisation for other reasons; n = 8).
Age
group














61–65 Etoposide, rituximab Supraventricular
tachycardia
Possible ADR of the drug
itself





Possible Both >90 Yes 11 6




Possible Both 25 No Unknown 7





71–75 Phenprocoumon Cerebral bleeding Possible ADR of the drug
itself
57 Yes Unknown 5
76–80 Phenprocoumon Cerebral bleeding Possible ADR of the drug
itself
>90 No 3 6
71–75 Phenprocoumon Subdural
haematoma
Possible ADR of the drug
itself





Possible ADR caused by
DDI
9 No Unknown 8
DDI = drug-drug interaction; eGFR = estimated glomerular filtration rate
Table 5: Cases reported to the Swiss national pharmacovigilance centre (n = 8).
Age
group

















Recovered Yes 4 4
71–75 Nadroparin Heparin-induced
thrombocytopenia
Yes No Certain Recovered Yes 3 10
91–95 Venlafaxine Hypertension exac-
erbated
Yes No Possible Recovered No 2 10
61–65 Metamizole Agranulocytosis, Ab-
scess perianal








Yes No Possible Recovered Yes 21 10
46–50 Clindamycin Maculo-papular ex-
anthema
Yes No Possible Recovered No 4 1




Recovered Yes 7 4
ADR: adverse drug reaction * No ADR after normalisation of tacrolimus concentration
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In our study, ADR-related emergency readmissions corre-
sponded to 21% of emergency readmissions and 6% of all
readmissions within 30 days after discharge. According to
a recent systematic review [7], rates of drug-related read-
missions in previous studies were 3–64% (median 21%).
The follow-up time between first admission and readmis-
sion in these studies varied from 28 days to more than 4
years, but readmission within 30 days was the most com-
monly used measure [7]. Besides data on the rates and
causes of readmissions, other aspects such as the patients’
emotional costs, loss of quality of life and economic bur-
den should also be considered for the estimation of the
global clinical and economic consequences related to hos-
pital readmissions. Although these were not assessed in
the current study, previous studies from the United States
report approximately 20% rate of rehospitalisations of
Medicare patients within 30 days after discharge with an
estimated annual cost of unplanned rehospitalisations of
US$17 billion [21].
In a previous study investigating ADR-related emergency
department visits leading to hospitalisation among adults
≥65 years of age [22], warfarin / oral antiplatelet agents
and insulins / oral hypoglycaemic agents were the impli-
cated drugs / drug classes in two-third of the cases, where-
as high-risk drugs, as defined by the Healthcare Effec-
tiveness Data and Information Set (HEDIS) measure for
“Use of high-risk medications in the elderly” [23], were
involved in only a minority of the cases. In another study
from the same group [24], investigating emergency depart-
ment visits for ADRs involving medications identified as
potentially inappropriate based on the Beers criteria (a con-
sensus-based and repeatedly updated list of medications
considered potentially inappropriate for use in patients ≥65
years of age, mostly owing to a high risk for adverse events
[25]), three drugs (warfarin, insulin, digoxin) were im-
plicated in one-third of the cases, whereas Beers criteria
medications caused lower numbers of emergency depart-
ment visits. Similar findings have been reported in studies
in geriatric patients (≥80 years of age) with ADR-related
readmission within 30 days, in which anticoagulants / an-
tiplatelet agents and bleeding were the most common drug
classes and adverse event [9]; prescription of nervous sys-
tem drugs (third most frequent drug class in our study) was
identified as a risk factor for ADR-related readmissions
within 30 days in a previous study with elderly patients
[13]. Although our study also included younger patients,
antithrombotic agents and bleeding complications (e.g.,
gastrointestinal, epistaxis, haematuria, haematoma) were
among the most commonly reported drugs and disorders,
and bleeding was the underlying ADR in five of the eight
fatal cases. These findings have important clinical impli-
cations, since such reactions (also known as Type A or
pharmacological ADRs) are largely dose dependent with
known mechanisms and therefore preventable [26]. This is
different from idiosyncratic reactions (also known as Type
B or hypersensitivity ADRs), such as many cases of drug-
induced liver injury or allergic skin reactions which are
less influenced by dosage and often are immunological-
ly mediated [26]. Therefore, future strategies to prevent
ADRs and ADR-related readmissions should focus not on-
ly on available lists of potentially inappropriate medica-
tions for specific age groups as listed in the Beers criteria
[25] or the German PRISCUS list [27], but also on other
considerations such as comorbidities and DDIs that can
lead to Type A reactions, and adequate follow-up for a
timely check for preventable ADRs, especially in patients
treated with anticoagulants and/or antiplatelet agents. Pre-
ventive measures to decrease Type A ADRs could include
automated red flags and DDI alerts in electronic medical
records based on patient profiles and laboratory values to
provide reminders for, e.g., a dose reduction based on the
renal function or a pharmacodynamic interaction with in-
creased risk of bleeding in the case of a combination of,
for example, an anticoagulant agent and a nonsteroidal
anti-inflammatory drug (NSAID). Furthermore, pharma-
cist- or clinical pharmacologist-led medication reconcilia-
tion interventions could further contribute to the reduction
of medication discrepancies and ADRs [28, 29]. In the case
of Type B reactions, some could be prevented with validat-
ed pharmacogenetic testing (e.g., human leucocyte antigen
(HLA)-B*5701 and associated increased risk for hypersen-
sitivity reactions to abacavir [30]).
Most of the patients in our study belonged to the elderly
group and ADR-related cases were significantly older than
non-ADR-related cases, most probably as a result of fac-
tors such as polypharmacy, impaired renal function or oth-
er comorbidities, which are common among older patients.
The complexity of medication regimens, which is calcu-
lated on the basis of number of prescribed drugs, dosage
form and frequency, and additional instructions has also
been shown to be predictive for unplanned hospital read-
missions within 30 days in previous studies [31]. Not all
of those factors were investigated in our study (and a high
medication regimen complexity score might also lead to
readmission due to lower adherence and not due to an
ADR) [31]. However, a median of 8 drugs, extending up
to 22 drugs on readmission, can be taken as an indicator
of a rather high complexity of medication regimens in the
ADR-related cases in our study. The large majority of the
cases were readmitted from home, whereas only one-fifth
of the patients were readmitted from another medical insti-
tution. Returning home after discharge was identified as a
risk factor for emergency readmission within 30 days al-
so in another matched case-control study with elderly pa-
tients, after adjustment for sex and age [13]. These find-
ings also highlight the importance of regular follow-up as
a strategy to prevent ADR-related readmissions, since it
can be assumed that patients in medical institutions re-
ceive more regular and thorough medical supervision than
patients at home. In a previous prospective cohort study
investigating preventability of ADRs among outpatients
[32], 63% of the ameliorable events were attributed to the
physician’s failure to respond to drug-related symptoms
and 37% to the patient’s failure to report the symptoms to
the physician. Regular follow-up with enough time avail-
able to check the patient’s medication list regarding indi-
cation, correct dosage and DDIs, and also to ask the pa-
tient about any potential drug-related symptoms can thus
contribute to the prevention of ADRs. In contrast to pre-
vious studies [6, 10], we did not find a significant differ-
ence in the duration of hospitalisation of the ADR-relat-
ed and the non-ADR-related cases, which might be in part
attributable to different hospital discharge policies among
countries. In our study, there was no significant difference
in the days between first hospitalisation for ADR- vs non-
ADR-related readmission; in a previous study no signif-
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icant difference regarding the delay between hospitalisa-
tions was found in patients with only one ADR-related
hospitalisation and patients hospitalised twice or more ow-
ing to ADRs [33].
Only a minority (8 of the 270 cases) of the ADRs in our
study were reported to the regulatory authorities, although
all cases identified led to (re-) hospitalisation and thus for-
mally fulfilled the criteria for seriousness. This highlights
one of the major limitations of pharmacovigilance data,
which are plagued by high underreporting rates [34]. Rea-
sons for underreporting include lack of time or unaware-
ness of reporting requirements; for example, the medical
personnel may not be aware that expected or only sus-
pected ADRs also could or must (in the case of serious
ADRs) be reported [12, 34]. Based on the reported cases
in our study, it seems that the decision to report a case
may have been based more on the clinical presentation
rather than the formal criteria for seriousness of the ad-
verse reaction. Another possible factor favouring reporting
could be knowledge of the possible adverse reactions of
the drugs, since many of the reported cases referred to
well-described ADRs of the specific agents (e.g., agranu-
locytosis associated with metamizole, liver injury associ-
ated with paracetamol, exanthemas associated with antibi-
otics, heparin-induced thrombocytopenia). However, none
of the fatal cases had been reported, which might be due to
lack of time (especially in an emergency setting), unaware-
ness regarding reporting requirements [34] or fear of pos-
sible legal consequences. Although currently not the case
in Switzerland, policies such as the Hospital Readmission
Reduction Program [35] have been introduced in the Unit-
ed States to reduce readmissions, by, for example, impos-
ing payment penalties on hospitals with excessive read-
missions for specific diagnoses, and similar developments
are seen in some European countries [7, 36]. Since sponta-
neous reports are a useful drug safety evaluation tool and
can generate signals, which can then be followed more
closely, it is important to raise awareness regarding the im-
portance of pharmacovigilance among medical personnel
and also to clarify relevant aspects such as the anonymity
of the reports and that proof of causality is not required.
In addition, organisation of ADR monitoring systems by
clinical pharmacologists and/or pharmacists within hospi-
tals could also significantly contribute to the timely recog-
nition and reporting of ADRs to the regulatory authorities.
Limitations of our study include the retrospective design,
with some missing information in some cases, and data
from only one emergency department, which may not be
representative for the whole country or other health sys-
tems. Furthermore, most cases were assessed as “possible”
and only few cases as “probable/likely” or “certain” based
on the formal causality criteria, and our data represent pre-
scription patterns that reflect clinical practice during the
observation period of the study, and new drug categories
(e.g., direct oral anticoagulants) have been introduced into
the Swiss market since then. It is also possible that newly
introduced ADR screenings by clinical pharmacologists
and pharmacists on hospital wards have contributed to in-
creased ADR reporting in the recent years. We investigat-
ed emergency department readmissions, and thus the total
number of ADR-related readmissions is most likely higher,
since cases admitted directly to a hospital ward (>70% of
the total readmissions) were not included in the analysis.
The strengths of the study include the sensitive search, the
individual review of the cases and the investigation of the
reporting frequency to drug regulatory authorities. To our
knowledge, this is the first study to investigate the frequen-
cy and characteristics of ADR-related emergency readmis-
sions in a large Swiss University Hospital. It could thus
contribute to public health by offering guidance regarding
ADR preventive measures and also raise awareness regard-
ing the importance of ADR reporting as a drug safety tool.
In conclusion, ADR-related readmissions constituted a
considerable part of short-term emergency readmissions,
with potentially preventable ADRs (e.g., bleeding, which
might have been prevented by more regular measurement
of the international normalised ratio (INR), prescription of
a proton pump inhibitor together with NSAID to prevent
gastroduodenal toxicity, dental hygiene and regular dental
visits in case of bisphosphonates) involved in many of the
cases. Despite being a relevant cause for rehospitalisation,
only a minority of the ARDs were reported to the regulato-
ry authorities. Strategies to prevent ADR-related readmis-
sions and to improve reporting rates are needed.
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Table S1: Adverse reactions and drugs involved by Anatomical Therapeutic Chemical (ATC) code (>1 drug involved in some cases, n = 477 drugs).
ATC
code
Drug group (ATC classification, 4th lev-
el, chemical subgroup)
n % Active ingredients Adverse reactions (LLT)
A ALIMENTARY TRACT AND METABO-
LISM
6 1.3
A02BC Proton pump inhibitors 1 0.2 Esomeprazole (1) Obstipation
A10AB Insulins and analogues for injection, fast-
acting
2 0.4 Insulin aspart (2) Hypoglycaemia
A10AE Insulins and analogues for injection, long-
acting
1 0.2 Insulin glargine (1) Hypoglycaemia
A10BA Biguanides 1 0.2 Metformin (1) Lactic acidosis syndrome
A12AX Calcium, combinations with vitamin D and/
or other drugs
1 0.2 Cholecalciferol (1) Obstipation
B BLOOD AND BLOOD FORMING OR-
GANS
118 24.7
B01AA Vitamin K antagonists 35 7.3 Phenprocoumon (33), Aceno-
coumarol (2)
Abdominal wall haematoma, anaemia, bleeding postopera-
tive, cerebral bleeding, epistaxis, gastrointestinal tract bleed
NOS, haematemesis, haematochezia, haematoma post ves-
sel puncture, haematoma postoperative, haemothorax, in-
tracerebral haemorrhage, joint bleeding, macroscopic
haematuria, muscle bleeding, pelvic haematoma, postopera-
tive haematoma, subdural haematoma, upper gastrointesti-
nal bleeding
B01AC Platelet aggregation inhibitors excl. heparin 45 9.4 Acetylsalicylic acid (32), Clopi-
dogrel (13)
Bladder tamponade, bleeding postoperative, bleeding vari-
cose vein, epistaxis, exanthema, gastrointestinal tract bleed
NOS, haematochezia, haematoma post vessel puncture,
haemorrhage oral, haemothorax, lower gastrointestinal
bleeding, macroscopic haematuria, muscle bleeding, upper
gastrointestinal bleeding, wound haematoma
B01AB Heparin group 36 7.5 Nadroparin (17), Enoxaparin
(13), Dalteparin (3), Heparin
(3)
Anaemia, bladder tamponade, bleeding postoperative,
breast bleeding, chronic subdural haematoma, haema-
tochezia, haematoma post vessel puncture, haematoma
postoperative, haemothorax, heparin-induced thrombocy-
topenia, intracerebral haemorrhage, lower gastrointestinal
bleeding, macroscopic haematuria, muscle bleeding, post-
operative haematoma, radiation proctitis, subdural
haematoma, upper gastrointestinal bleeding
B03AA Iron bivalent, oral preparations 1 0.2 Ferrous 2+ (1) Obstipation
B01AX Other antithrombotic agents 1 0.2 Fondaparinux (1) Haemothorax
C CARDIOVASCULAR SYSTEM 24 5.0
C03AA Thiazides, plain 1 0.2 Hydrochlorothiazide (1) Hyponatraemia
C03BA Sulfonamides, plain 9 1.9 Torsemide (5), Metolazone
(3), Furosemide (1)
Acute prerenal failure, aute renal failure, arthritis gouty, hy-
potonic dehydration, prerenal insufficiency
C03EA Low-ceiling diuretics and potassium-spar-
ing agents
1 0.2 Amiloride + Hydrochloroth-
iazide (1)
Hyponatraemia
C10AA HMG-CoA reductase inhibitors 1 0.2 Rosuvastatin (1) Drug-induced liver injury
C08CA Dihydropyridine derivates 1 0.2 Lercanidipine (1) Acute renal failure
C07CB Beta blocking agents, selective, and other
diuretics
1 0.2 Atenolol + Chlorthalidone Orthostatic presyncope
C07AB Beta blocking agents, selective 2 0.4 Metoprolol (1), Nebivolol (1) Fatigue, obstipation
C09DA Angiotensin-II receptor blockers (ARBs)
and diuretics
1 0.2 Candesartan + Hydrochloroth-
iazide (1)
Hyponatraemia
C09CA Angiotensin-II receptor blockers (ARBs),
plain
2 0.4 Telmisartan (1), Olmesartan
(1)
Orthostatic presyncope, acute renal failure
C03DA Aldosterone antagonists 3 0.6 Spironolactone (3) Decompensated cirrhosis, acute prerenal failure, prerenal
insufficiency
C09BA ACE inhibitors and diuretics 1 0.2 Perindopril + Indapamide (1) Acute renal failure
C09AA ACE inhibitors, plain 1 0.2 Lisinopril (1) Acute pancreatitis
G GENITO URINARY SYSTEM AND SEX
HORMONES
2 0.4
G01AF Imidazole derivates 1 0.2 Metronidazole (1) Convulsion
G04BD Drugs for urinary frequency and inconti-
nence
1 0.2 Tolterodine (1) Obstipation
H SYSTEMIC HORMONAL PREPARA-
TIONS, EXCL. SEX HORMONES AND IN-
SULINS
50 10.5
H02AB Glucocorticoids 50 10.5 Prednisolone (42), Hydrocorti-
sone (3), Dexamethasone (3),
Deflazacort (1), Prednisone
(1)
Abdominal abscess, abscess dental, acute osteomyelitis,
adrenocortical insufficiency acute, ascites infection, as-
pergillosis, chills and fever, cholangitis, CMV infection, con-
fusion, drug psychoses, erysipelas, Escherichia coli bacter-
aemia, fever, gonarthritis, infection, MRSA wound infection,
perforation colon, pneumonia, postoperative wound infec-
tion, pyelonephritis, secondary adrenal insufficiency, septi-
caemia, spondylodiscitis, surgical wound infection, upper
Original article Swiss Med Wkly. 2021;151:w20400
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”. No commercial reuse without permission - https://smw.ch/permissions
Page 11 of 14
ATC
code
Drug group (ATC classification, 4th lev-
el, chemical subgroup)
n % Active ingredients Adverse reactions (LLT)
gastrointestinal bleeding, urosepsis, wound dehiscence,
wound healing delayed, wound healing disturbance of,
wound infection, wound infection bacterial, wound sepsis
J ANTIINFECTIVES FOR SYSTEMIC USE 26 5.5
J01DH Carbapenems 3 0.6 Ertapenem (2), Meropenem
(1)
Clostridium difficile infection recurrence, Clostridium difficile
colitis
J01DD 3rd Generation cephalosporins 2 0.4 Ceftriaxone (2) Clostridium difficile infection recurrence, anaphylactic reac-
tion to drug
J01DE 4th Generation cephalosporins 1 0.2 Cefepime (1) Clostridium difficile colitis
J01MA Fluorquinolones 3 0.6 Ciprofloxacin (3) Fever, electrocardiogram QT prolonged, macroscopic
haematuria
J01CR Combinations of penicillins, incl. beta-lacta-
mase inhibitors
10 2.1 Amoxicillin + Clavulanic acid
(10)
Antibiotic-associated diarrhoea, clonic-tonic convulsions,
Clostridium difficile colitis, Clostridium difficile infection re-
currence, colitis, convulsion, drug-induced liver injury, gas-
troenteritis noninfectious, maculo-papular exanthema
J01FF Lincosamides 2 0.4 Clindamycin (2) Electrocardiogram QT prolonged, maculo-papular exanthe-
ma
J01FA Macrolides 3 0.6 Clarithromycin (3) Haematoma postoperative, clonic-tonic convulsions, leuco-
cytoclastic vasculitis
J01CA Penicillins with extended spectrum 1 0.2 Amoxicillin (1) Maculo-papular exanthema
J05AE Protease inhibitors 1 0.2 Ritonavir (1) Drug-induced delirium
L ANTINEOPLASTIC AND IMMUNOMODU-
LATING AGENTS
169 35.4
L01AX Other alkylating agents 3 0.6 Temozolomide (3) Febrile aplasia, polyneuropathy, maculo-papular exanthema
L01XX Other antineoplastic agents 1 0.2 Hydroxycarbamide (1) Febrile aplasia
L04AX Other immunosuppressants 5 1.0 Azathioprine (5) Acute osteomyelitis, erysipelas, pneumonia, pyelonephritis,
urosepsis
L01DC Other cytotoxic antibiotics 1 0.2 Bleomycin (1) Embolism pulmonary
L01DB Anthracyclines and related substances 14 2.9 Doxorubicin (12), Epirubicin
(1), Mitoxantrone (1)
Escherichia sepsis, febrile aplasia, febrile neutropenia,
fever, pneumonia, urosepsis, viral upper respiratory tract in-
fection, vomiting post chemotherapy
L04AD Calcineurin inhibitors 22 4.6 Ciclosporin (15), Tacrolimus
(7)
Abscess dental, abscess jaw, ascites infection, cholangitis,
CMV infection, confusion, convulsion, drug overdose acci-
dental, erysipelas, Escherichia coli bactearemia, fever, pan-
cytopenia, pneumonia, postrenal failure, pyelonephritis,
spondylodiscitis, urosepsis
L01BA Folic acid analogues 1 0.2 Pemetrexed (1) Nausea post chemotherapy
L03AB Interferons 1 0.2 Interferon alpha-2a (1) Pseudomonal sepsis
L03AA Colony stimulating factors 1 0.2 Filgrastim (1) Low back pain
L01XB Methylhydrazines 1 0.2 Procarbazine (1) Fever
L01XC Monoclonal antibodies 16 3.4 Rituximab (13), Cetuximab
(1), Pertuzumab (1),
Trastuzumab (1)
Angina agranulocytic, diarrhoea, Escherichia sepsis, febrile
aplasia, febrile neutropenia, fever, neutropenic colitis, pan-
cytopenia, pneumonia, supraventricular tachycardia, toxic
epitheliolysis, urosepsis, viral upper respiratory tract infec-
tion
L01XA Platinum compounds 16 3.4 Cisplatin (10), Carboplatin (4),
Oxaliplatin (2)
Asthenia, embolism pulmonary, enterocolitis, febrile aplasia,
hypertension exacerbated, hyponatraemia, nausea post
chemotherapy, obstipation, pyelonephritis fungal, rRenal in-
farction, septic cholangitis, vomiting post chemotherapy
L01CB Podophyllotoxin derivates 11 2.3 Etoposide (11) Febrile aplasia, febrile neutropenia, fever, neutropenic coli-
tis, supraventricular tachycardia
L01XE Protein kinase inhibitors 3 0.6 Sorafenib (2), Imatinib (1) Tachycardia, diarrhoea, acute cholecystitis
L01BB Purine analogues 1 0.2 Fludarabine (1) Angina agranulocytic




Enterocolitis, Escherichia sepsis, febrile aplasia, heart fail-
ure NYHA class III, infection, neutropenic colitis, obstipation,
pyelonephritis fungal, septic cholangitis, sinusitis, vomiting
post chemotherapy
L04AA Selective immunosuppressants 20 4.2 Mycophenolic acid (15),
Everolimus (3), Sirolimus (1),
Antithymocyte immunoglobu-
lin (1)
Abdominal pain, abscess dental, ascites infection, CMV in-
fection, Escherichia coli bacteraemia, nausea and vomiting,
pancytopenia, pneumonia, postoperative wound infection,
postrenal failure, pyelonephritis, urosepsis, wound sepsis
L01AA Nitrogen mustard analogues 18 3.8 Cyclophosphamide (9), Ifos-
famide (6), Bendamustine (2),
Melphalan (1)
Angina agranulocytic, chills and fever, diarrhoea, Es-
cherichia sepsis, febrile aplasia, febrile neutropenia, fever,
neutropenic colitis, pancytopenia, urosepsis, viral upper res-
piratory tract infection
L01CD Taxanes 4 0.8 Docetaxel (3), Paclitaxel (1) Tracheobronchitis, enterocolitis, infection, pneumonia
L01CA Vinca alkaloids and analogues 16 3.4 Vincristine (12), Vinorelbine
(2), Vindesine (1), Vinflunine
(1)
Asthenia, Escherichia sepsis, febrile aplasia, febrile neu-
tropenia, fever, nausea post chemotherapy, urosepsis, viral
upper respiratory tract infection
M MUSCULO-SKELETAL SYSTEM 6 1.3
M01AE Propionic acid derivatives 1 0.2 Ibuprofen (1) Gastrointestinal tract bleed NOS
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ATC
code
Drug group (ATC classification, 4th lev-
el, chemical subgroup)
n % Active ingredients Adverse reactions (LLT)
M03BX Other centrally acting agents 2 0.4 Baclofen (2) Myoclonus, somnolence
M04AA Preparations inhibiting uric acid production 1 0.2 Allopurinol (1) Maculo-papular exanthema
M05BA Bisphosphonates 2 0.4 Ibandronic acid (1), Zolen-
dronic acid (1)
Jaw fracture, fever
N NERVOUS SYSTEM 74 15.5
N01AX Other general anesthetics 1 0.2 Propofol (1) Convulsions generalised
N06AX Other antidepressants 8 1.7 Venlafaxine (5), Mirtazapine
(3)
Clonic-tonic convulsions, sall, hypertension exacerbated,
obstipation, upper gastrointestinal bleeding
N03AX Other antiepileptics 3 0.6 Lamotrigine (1), Topiramate
(1), Levetiracetam (1)
Somnolence, hyperammonaemic encephalopathy, amnesia
N02AX Other opioids 2 0.4 Tramadol (2) Obstipation
N02BE Anilides 1 0.2 Paracetamol (acetaminophen)
(1)
Drug-induced liver injury
N05BA Benzodiazepine derivatives 6 1.3 Lorazepam (2), Oxazepam
(1), Clobazam (1), Fluni-
trazepam (1), Midazolam (1)
Amnesia, delirium, drug-induced delirium, dyspnoea, fall
N05CF Benzodiazepine related drugs 2 0.4 Zolpidem (2) Fall, dyspnoea
N03AF Carboxamide derivatives 4 0.8 Oxcarbazepine (4) Obstipation, hyponatraemia, amnesia, exanthema gener-
alised
N05AH Diazepines, oxazepines, thiazepines and
oxepines
2 0.4 Clozapine (1), Quetiapine (1) Cardiomyopathy, convulsions generalised
N04BC Dopamine agonists 3 0.6 Pramipexole (2), Ropinirole
(1)
Dyskinesia aggravated, obstipation, confusion
N04BA Dopa and dopa derivatives 1 0.2 Entacapone+ Levodopa+ Car-
bidopa (1)
Dyskinesia aggravated
N03AG Fatty acid derivatives 2 0.4 Valproic acid (2) Hyperammonaemic encephalopathy, somnolence
N03AB Hydantoin derivatives 1 0.2 Phenytoin (1) Maculo-papular exanthema
N07BA Drugs used in nicotine dependence 1 0.2 Nicotine (1) Leucocytoclastic vasculitis
N07BC Drugs used in opioid dependence 4 0.8 Methadone (4) Obstipation
N02AA Natural opium alkaloids 6 1.3 Oxycodone + Naloxone (4),
Oxycodone (1), Morphine (1)
Delirium, analgesic rebound headache, obstipation
N06AA Non-selective monoamine reuptake in-
hibitors
1 0.2 Trimipramine (1) Hyponatraemia
N02AB Phenylpiperidine derivatives 11 2.3 Fentanyl (10), Pethidine (1) Delirium, gastrointestinal motility disorder, ileus, nausea and
vomiting, obstipation, subileus
N02BB Pyrazolones 4 0.8 Metamizole (4) Agranulocytosis, nausea and vomiting, anaphylactic reaction
to drug
N02BA Salicylic acid and derivatives 1 0.2 Acetylsalicylic acid (1) Subdural haematoma
N06AB Selective serotonin reuptake inhibitors 10 2.1 Escitalopram (8), Citalopram
(1), Sertraline (1)
Bleeding postoperative, hyponatraemia, macroscopic
haematuria, obstipation, paraesthesia, pelvic hematoma, ra-
diation proctitis, somnolence
R RESPIRATORY SYSTEM 1 0.2
R03BB Anticholinergics 1 0.2 Ipratropium bromide (1) Obstipation
V VARIOUS 1 0.2
V03AF Detoxifying agents for antineoplastic treat-
ment
1 0.2 Calcium folinate (1) Septic cholangitis
ATC = Anatomical Therapeutic Chemical; CMV = cytomegalovirus; LLT = lowest level term; MRSA = methicillin-resistant Staphylococcus aureus; NOS = not otherwise specified;
NYHA = New York Heart Association
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Table S2: Cases classified as “probable/likely” according to the Swiss adverse drug reaction (ADR) reporting system causality criteria.
Adverse drug reaction (LLT) Cases (n) Drugs (n)
Clostridium difficile colitis 3 Amoxicillin + Clavulanic acid (2), Ertapenem (1)
Nausea post chemotherapy 2 Cisplatin (1), Vinorelbine, Carboplatin (1)
Adrenocortical insufficiency acute 1 Prednisolone (1)
Anaphylactic reaction to drug 1 Ceftriaxone (1)
Bleeding postoperative 1 Phenprocoumon (1)
Cardiomyopathy 1 Clozapine (1)
Clonic-tonic convulsions 1 Venlafaxine (1)
Drug psychoses, other 1 Dexamethasone (1)
Drug-induced delirium 1 Ritonavir, Midazolam (1)
Enterocolitis 1 Cisplatin, Docetaxel, Fluorouracil (1)
Epistaxis 1 Phenprocoumon (1)
Exanthema generalised 1 Oxcarbazepine (1)
Gastroenteritis noninfectious 1 Amoxicillin + Clavulanic acid (1)
Hypoglycaemia 1 Insulin aspart (1)
Hyponatraemia 1 Hydrochlorothiazide, Oxcarbazepine, Citalopram (1)
Hypotonic dehydration 1 Metolazone, Torasemide (1)
Jaw fracture 1 Ibandronic acid (1)
Joint bleeding 1 Phenprocoumon (1)
Low back pain 1 Filgrastim (1)
Paraesthesia 1 Escitalopram (1)
Secondary adrenal insufficiency 1 Hydrocortisone (1)
LLT = lowest level term
Table S3: Cases requiring admission to the intensive care unit (assessed as “life-threatening”; n = 34).
Adverse drug reaction n
Upper gastrointestinal bleeding 5







Clostridium difficile colitis 1
Convulsion 1
Epistaxis 1
Escherichia coli bacteraemia 1
Fatigue* 1




Lactic acidosis syndrome 1
Postoperative wound infection 1
Somnolence† 1
Vomiting post chemotherapy 1
Wound haematoma 1
* Road traffic accident; † somnolence, dysarthria, anomia, walking disability
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